Breast Cancer Clinical Trial

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

Summary

The purposes of this study are to determine whether pemetrexed can help patients with metastatic (cancer that has spread to other parts of the body) breast cancer, to determine any side effects that may be associated with the drug, to determine how much pemetrexed should be given to patients, and to collect DNA for future research regarding metastatic breast cancer. The collection of DNA is optional to the patient.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Must have been diagnosed with either advanced or metastatic breast cancer.
Chemotherapy has not been given for advanced or metastatic breast cancer.
The diagnosis of advanced or metastatic breast cancer was made at least 12 months after chemotherapy was given after breast surgery.
Able to carry out work of a light nature (for example, light housework, office work).
Must be at least 18 years old.

Exclusion Criteria:

Have received prior bone marrow or peripheral stem cell transplantation.
Have received prior chemotherapy for metastatic breast cancer.
Are currently pregnant or breast-feeding.
Have an active infection that your doctor decides will affect your safety.
Are unable to take folic acid or vitamin B12.

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

37

Study ID:

NCT00106002

Recruitment Status:

Completed

Sponsor:

Eli Lilly and Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Dallas Texas, 75204, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

37

Study ID:

NCT00106002

Recruitment Status:

Completed

Sponsor:


Eli Lilly and Company

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider